Reaction

Nipple Pain reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,009 reports · 40 co-occurring drugs

As of the last recalculation, Nipple Pain appears in 2,009 FAERS reports alongside 40 co-occurring drug terms. The strongest observed disproportionality signal is HYDROCORTISONE SODIUM SUCCINATE (PRR 33.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Hydrocortisone Sodium Succinate	30	33.5	33.7
Esomeprazole Magnesium Capsule, Delayed Release	30	21.7	21.8
Esomeprazole Magnesium Delayed Release Capsules	30	21.7	21.8
Esomeprazole Magnesium Dihydrate	30	21.6	21.7
Finasteride	113	20.5	20.5
Leucovorin Calcium	37	20.4	20.5
Levonorgestrel	245	14.2	14.2
Bicalutamide	18	12.3	12.4
Estradiol	90	11.3	11.3
Labetalol	13	10.2	10.2
Sumatriptan Succinate	24	9.9	10.0
Sorafenib	19	9.6	9.6
Enzalutamide	51	9.2	9.2
Dutasteride	7	8.9	9.0
Terazosin Hydrochloride	7	8.2	8.2
Spironolactone	102	7.9	7.9
Sumatriptan	27	7.4	7.4
Eplerenone	9	7.3	7.3
Progesterone	16	7.3	7.3
Vemurafenib	8	6.9	6.9
Estradiol Gel 0.1%	28	6.5	6.5
Estradiol Transdermal	28	6.5	6.5
Conjugated Estrogens	34	6.1	6.1
Estrogens, Conjugated	34	6.0	6.0
Etonogestrel And Ethinyl Estradiol	12	5.6	5.6
Etonogestrel	24	5.3	5.3
Leuprolide Acetate	38	5.2	5.2
Vedolizumab	38	4.6	4.6
Relugolix	10	4.4	4.4
Tafamidis	5	4.4	4.4
Minoxidil Foam 5% (Womens)	13	4.1	4.1
Glecaprevir And Pibrentasvir	4	3.8	3.8
Sacubitril And Valsartan	41	3.7	3.7
Siponimod	3	3.5	3.5
Dasatinib	12	3.4	3.4
Minoxidil	13	3.0	3.0
Fremanezumab-Vfrm	3	2.7	2.7
Apalutamide	3	2.6	2.6
Paliperidone Palmitate	6	1.9	1.9
Copper	6	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.